Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

BI-3802

  Cat. No.:  DC20779   Featured
Chemical Structure
2166387-65-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
BI-3802 (BI3802) is a highly potent and effective BCL6 degrader that disrupts the interaction between the BTB/POZ domain of BCL6 and its co-repressors in vitro, achieving an IC50 of less than 3 nM.
Cas No.: 2166387-65-9
Chemical Name: BI-3802
Synonyms: 2-((6-((5-Chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)oxy)-N-methylacetamide;2-[6-[[5-Chloranyl-2-[(3~{s},5~{r})-3,5-Dimethylpiperidin-1-Yl]pyrimidin-4-Yl]amino]-1-Methyl-2-Oxidanylidene-Quinolin-3-Yl]oxy-~{n}-Methyl-Ethanamide;U52;BI-3802
SMILES: ClC1=CN=C(N=C1NC1C=CC2=C(C=C(C(N2C)=O)OCC(NC)=O)C=1)N1C[C@H](C)C[C@H](C)C1
Formula: C24H29ClN6O3
M.Wt: 484.9785
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: BI-3802 (BI3802) is a highly potent and efficacious BCL6 degrader that potently inhibits the interaction of the BTB/POZ domain of BCL6 with several co-repressors in vitro with IC50 of <3 nM; inhibits the BCL6/Co-repressor complex formation with IC50 of 43 nM in vitro, also is a potent and efficacious degrader of the BCL6 protein in many DLBCL cell lines (DC50=20 nM in SU-DHL-4 cells); BI-3802 is a valuable probe compound for testing hypotheses around BCL6 biology.
Cat. No. Product name Field of application
DC60948 NEK7 degrader (Compound 17) NEK7 degrader-1 is a NEK7 molecular glue degrader with a DC50 of 9  nM. NEK7 degrader-1 dose-dependently inhibits caspase-1 activity and IL-Ιβ release in macrophages in response to NLRP3 inflammasome activation. NEK7 degrader-1 can be used for autoinflammatory and autoimmune disorders like multiple sclerosis, neurodegeneraive diseases like Alzheimer's disease and cardiovascular and melabolic disorders like pericarditis and Type 2 diabetes research.
DC68076 BG-BRD4-P07
DC68075 BRU-SHP2-P06
DC68074 LLY-ESR1-P05
DC68073 AST-AR-P04
DC68072 NOV-EP001
DC68071 JHU-MDM2-P03
DC68070 CAS-FAK-P02
DC68069 MDA-S24-P01
DC68068 TB-008
X